TII
10.11.2020 13:09:04 CET | Business Wire | Press release
Abu Dhabi has unveiled the Technology Innovation Institute (TII), a pioneering global centre for advanced technology research committed to reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation and advanced technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005653/en/
The institute is the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), which was recently established to set the research and development (R&D) priorities for Abu Dhabi.
It aims to deliver discovery science and breakthrough technologies that have a global impact. It is rapidly breaking new ground at its seven initial dedicated research centres, which each have world-class research facilities.
The initial seven areas of focus are: quantum research; autonomous robotics; cryptography; advanced materials; digital security; directed energy; and secure systems.
His Excellency Faisal Al Bannai, Secretary-General of Advanced Technology Research Council, said the institute would help position Abu Dhabi and the UAE as a global hub for advanced technology research.
HE Faisal said: “The Technology Innovation Institute is a pioneering research centre that develops disruptive and transformative technologies that have practical use-cases and global impact. The institute allows us to push the frontiers of knowledge further than ever before for the benefit of science, society, the economy and the environment.”
Teams of international scientists and researchers joined the institute from around the world within two months of the first board meeting in August 2020. This intellectual community will contribute to building a research and development (R&D) ecosystem in Abu Dhabi and the UAE.
TII will also drive applied research, intellectual property development, and academic and industry partnerships. It has already begun working on more than 25 long-term collaborative projects through partnerships with more than 20 world-leading universities.
Importantly, the institute will have the flexibility to rapidly progress research, with a defined research roadmap, committed long-term funding and the ability to make effective decisions in a fast-paced environment.
TII is one of two pillars under ATRC, which was established in May 2020 to expand the breadth and depth of an already thriving R&D ecosystem in Abu Dhabi. Bringing together cross-disciplinary leaders in research and technology, ATRC is cultivating a collaborative research community, accelerating innovation and discovery and fostering a culture of inquiry.
About Technology Innovation Institute (TII):
Technology Innovation Institute, the dedicated applied research pillar of the Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres, in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the institute connects an intellectual community and contributes to expanding the R&D ecosystem in Abu Dhabi and the UAE. The institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of a knowledge-based economy.
For more information, visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005653/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom